New Portfolio and Lower Longer Outcomes Relapse to Phase SOLARIS to to Showing Rates Options Data of Compared of Incidence 3 No Treatment Presents Teva (olanzapine) Date
https://financialpost.com/globe-newswire/teva-presents-latest-schizophrenia-portfolio-data-including-real-world-outcomes-with-uzedy-risperidone-showing-lower-rates-of-and-longer-time-to-relapse-compared-to-oral-treatment-options-and with UZEDY® Time Including and (risperidone) PDSS Schizophrenia TEV-‘749 Oral Real-World Showing Data with Latest